Will Apollomics stock go up?

According to Danelfin AI, Apollomics has today an AI Score of 1/10 (Strong Sell rating), because its probability of beating the market in 3 months (37.37%) is -13.45% vs. the average probability (50.82%) of all US-listed stocks.

What is the target price for Apollomics stock?

The Apollomics target price is $19.58 (1Y), according to the average price target offered by analysts.

Is it a good time to buy, sell, or hold Apollomics stock right now?

Apollomics has today a Strong Sell rating (AI Score 1/10), according to Danelfin AI. Its probability of beating the market in 3 months (37.37%) is -13.45% vs. the average probability (50.82%) of all US-listed stocks, based on our AI-powered analysis. You can find more details on whether Apollomics stock is a good buy .

Is Apollomics undervalued right now?

Based on analysts, the average price target downside for Apollomics is 0.00% (1Y). According to Danelfin AI, Apollomics has today an AI Score of 1/10 (Strong Sell Rating).

What was the price range of Apollomics stock over the past 12 months?

The Apollomics stock price range over the past 12 months has been $3.93 - $36.65.

What is going on with Apollomics stock in the last 3 months?

The Apollomics stock performance in the last quarter has been +23.53%.

Does Apollomics offer dividend payments?

No, Apollomics does not currently pay dividends.

What is the current market capitalization of Apollomics?

Apollomics's market cap is $42.95M, as of 2026-07-03 08:00.

Apollomics Inc (APLM) AI Stock Analysis

Advanced Chart

Custom range

Jul 3, 2025

→

Jul 3, 2026

Custom range

Jul 3, 2025

→

Jul 3, 2026

APLM AI-Powered Stock Analysis

AI Score Explanation

AI Score

Strong Sell

Fundamental
Technical
Sentiment
Low Risk

According to Danelfin’s proprietary AI model, Apollomics Inc today receives an AI Score of 1/10, which translates to a Strong Sell rating. The stock has a 37% probability of outperforming the market in the next 3 months, which is 14% lower than the average probability of any stock (51%). The top positive contributors include the Chart Pattern (252d) (impact +2.12%) and Chart Pattern (90d) (impact +0.73%), both indicating favorable technical formations, along with Alpha 1Y (impact +0.72%, in the top 10%) and Short Float (%) (impact +0.44%, in the bottom 10%). The main detractors are the Fundamentals Impact (Long Tail) (impact -4.02%), Maximum Volatility (impact -2.15%, in the top 10%), ATR (14d Volatility) (impact -1.71%, in the top 30%), Analyst Mean Price Target Upside (impact -1.26%, in the bottom 10%), Fear & Greed Index (impact -1.26%), Institutional Ownership (impact -1.18%, in the bottom 10%), Technicals Impact (Long Tail) (impact -1.05%), Industry (GICS) (impact -0.91%), ATR (180d Volatility) (impact -0.63%, in the top 20%), Minimum Volatility (impact -0.58%, in the top 10%), Normalized Average True Range (50d) (impact -0.56%, in the top 30%), and Plus Directional Indicator (+DI, 90d) (impact -0.49%, in the top 10%). Notable data points include the Analyst Mean Price Target Upside at -89.58% (bottom 10%), indicating analysts expect significant downside, and Institutional Ownership at only 3% (bottom 10%), reflecting low confidence from large investors. Volatility metrics are extremely high, with Maximum Volatility in the top 10% and ATR (14d) in the top 30%, suggesting large price swings and risk. On the positive side, Alpha 1Y is in the top 10% with a value of 178.34%, showing strong risk-adjusted returns over the past year, and Short Float (%) is very low at 0.22% (bottom 10%), indicating minimal bearish sentiment. However, the overwhelming negative contributions from fundamentals, volatility, and analyst sentiment outweigh the positives, resulting in a Strong Sell rating. The stock faces significant headwinds, and the AI model sees a low probability of outperformance in the next 3 months.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

Momentum+0.69%
Direction and strength of recent price movements

Volatility-6.26%
How much the stock price tends to fluctuate
Valuation-4.02%
How the stock is priced relative to its fundamentals
Sentiment-3.86%
How analysts and the market view the stock

APLM probability advantage of beating the market (3M):

-13.45%

AI Score

Strong Sell

Apollomics (APLM) has an AI Score of 1/10 (Strong Sell) because, according to an overall analysis, it has a probability advantage of -13.45% of beating the market (S&P500) in the next 3 months. This advantage is calculated as the difference between the average probability of any US-listed stock (50.82%) and the probability of APLM (37.37%) of outperforming the market in the next 3 months, as determined by Danelfin AI’s comprehensive analysis.

Average probability of any US-listed stock of beating the market (3M)50.82%
APLM probability advantage of beating the market (3M)-13.45%
APLM probability of beating the market (3M)37.37%

APLM probability advantage of beating the market (3M): -13.45%

The AI-powered overall analysis of Apollomics (APLM) is based on the 25 fundamental, technical, and sentiment features that had the greatest impact on stock performance during the last 12 months (alpha signals). These alpha signals explain the probability advantage of APLM:

Type	Alpha Signal	Current Value	Value Decile Position	Probability Advantage Impact (3M)
Fundamental	Fundamentals Impact (Long Tail)	-	N/A	-4.02%
Technical	Maximum Volatility	21.38%		-2.15%
Technical	Chart Pattern (252d)	figure_18	N/A	+2.12%
Technical	ATR (14d Volatility)	2.2		-1.71%
Sentiment	Analyst Mean Price Target Upside	-0.90%	N/A	-1.26%
Sentiment	Fear & Greed Index (CNN)	31	N/A	-1.26%
Sentiment	Institutional Ownership	0.03%	N/A	-1.18%
Technical	Technicals Impact (Long Tail)	-	N/A	-1.05%
Sentiment	Industry (GICS)	Biotechnology	N/A	-0.91%
Technical	Chart Pattern (90d)	figure_19	N/A	+0.73%
Technical	Upgrade to unlock			+0.72%
Technical	Upgrade to unlock			-0.63%
Technical	Upgrade to unlock			-0.58%
Technical	Upgrade to unlock			-0.56%
Technical	Upgrade to unlock			-0.49%

Rest of Alpha Signals: -1.21%

APLM probability advantage of beating the market (3M)Total:-13.45%
APLM AI Score

Significant changes Vs previous day

APLM Short Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:$19.58
Horizon: 3 months
Stop Loss:$XXXXXPro (XXXXXPro)
Take Profit:$XXXXXPro (XXXXX
Pro
)

APLM Proven Sell Signal & Price Forecast

This is the price chart for APLM from January 2, 2026 until today. The chart indicates, in red, the 112 days when the stock received a Sell/Strong Sell rating (sell signals, AI Score 1 to 3).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Sell signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Sell signals

Forecast:

1 Month
3 Months
6 Months
1 Year

APLM Average Past Performance & Loss Rate

Three months after its 811 Sell signals since July 2026, APLM had an average performance of xxxxxx and a xxxxxx Loss rate (negative performance).

811 Past APLM Sell Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				-55.51%
Average Alpha				-75.01%
Loss Rate (% Negative Perf.)				82.83%
% Negative Alpha				85.05%

APLM Frequently Asked Questions

Will Apollomics stock go up?
According to Danelfin AI, Apollomics has today an AI Score of 1/10 (Strong Sell rating), because its probability of beating the market in 3 months (37.37%) is -13.45% vs. the average probability (50.82%) of all US-listed stocks.
What is the target price for Apollomics stock?
Is it a good time to buy, sell, or hold Apollomics stock right now?
Is Apollomics undervalued right now?
What was the price range of Apollomics stock over the past 12 months?
What is going on with Apollomics stock in the last 3 months?
Does Apollomics offer dividend payments?
What is the current market capitalization of Apollomics?

Apollomics Inc Company Profile

Apollomics, Inc., a clinical-phase biopharmaceutical firm, invests its resources in unearthing and advancing oncology treatments that effectively engage the immune system to specifically target key molecular pathways with the ultimate goal of eradicating cancer. The company's product suite is diversified, starting with Vebreltinib (APL-101), an orally active c-Met inhibitor demonstrating remarkable discrimination ability, currently under Phase 2 clinical examination for potential application against non-small cell lung cancer.

The portfolio also features APL-102, an orally operative Multiple Tyrosine Kinase Inhibitor undergoing Phase 1 clinical trials designed to inhibit anomalously activated kinases in cancer cells. Moreover, APL-122 is pursued as a promising tumor inhibitor candidate targeting ErbB1/2/4 signalling routes. It is also being subjected to Phase 1 dose escalation trials to devise treatment strategies for brain cancers.

In addition, Apollomics remains focused on the development of Uproleselan (APL-106). This innovative compound is currently examined in a Phase 3 trial intended for adult patients presenting relapsed or refractory AML; additionally, it's involved in a joint Phase 2/3 experiment with uproleselan engaged for therapy of newly diagnosed older adults carrying AML.

APL-108 concludes the portfolio - it’s an upgraded E-selective inhibitor that has successfully passed through a Phase 1 trial aimed at addressing both liquid and solid tumor variants.

Looking further into its pipeline reveals several preclinical immuno-oncology product candidates including APL-501, APL-502, APL-801 and APL-810. These ventures consist of inhibitors that arrest tumor proliferation, anti-cancer enhancers that augment the effectiveness of existing therapies, and immunotherapeutic drugs designed to stimulate the body's defenses against cancer.

Established under the banner CBT Pharmaceuticals, Inc., the company made a significant nomenclature transition, emerging as Apollomics, Inc. in January 2019. The firm was initially incorporated in 2015 and maintains its operational base in Foster City, California.

Sector:Health Care
Country:United States
Industry:
Address:989 East Hillsdale Blvd, Ste 220, Foster City
Employees:14
Website:apollomicsinc.com

Pros

Proprietary drug candidates with patent protection

Addressing oncology indications with unmet medical needs

Diversified clinical pipeline across multiple mechanisms

Potential for high pricing power for novel therapies

Strategic partnerships for co-development and commercialization

Cons

Substantial capital intensity for drug discovery and development

High probability of clinical trial failures

Future revenue dependency on limited product approvals

Intense competition from established pharmaceutical companies

Regulatory complexity across multiple geographic markets

APLM Stock AI Analysis High Risk

Apollomics Inc

APLM Stock AI Analysis

Apollomics Inc

APLM AI-Powered Stock Analysis

AI Score Explanation

AI Score Explanation

Generating AI Score explanation

AI Score Alpha Factors

Alpha Signals: What Drives the AI Score

APLM probability advantage of beating the market (3M): -13.45%

APLM Short Trading Parameters

APLM Proven Sell Signal & Price Forecast

APLM Average Past Performance & Loss Rate

APLM Frequently Asked Questions

Will Apollomics stock go up?

What is the target price for Apollomics stock?

Is it a good time to buy, sell, or hold Apollomics stock right now?

Is Apollomics undervalued right now?

What was the price range of Apollomics stock over the past 12 months?

What is going on with Apollomics stock in the last 3 months?

Does Apollomics offer dividend payments?

What is the current market capitalization of Apollomics?

Apollomics Inc Company Profile

Pros

Cons

Pros

Cons

APLM Company Profile Summary

APLM Related Investment Themes

APLM Related Stocks

APLM Top 10 Industry Stocks

Biotechnology

APLM Top 10 Sector Stocks

Health Care

APLM Stock AI Analysis High Risk

Apollomics Inc

NASDAQ NMS - GLOBAL MARKET

Will Apollomics stock go up?

What is the target price for Apollomics stock?

Is it a good time to buy, sell, or hold Apollomics stock right now?

Is Apollomics undervalued right now?

What was the price range of Apollomics stock over the past 12 months?

What is going on with Apollomics stock in the last 3 months?

Does Apollomics offer dividend payments?

What is the current market capitalization of Apollomics?

NASDAQ NMS - GLOBAL MARKET

APLM Proven Sell Signal & Price Forecast

Pros

Cons

AI Score Explanation